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Institute for Global Health, New South Wales, Australia; and 18Renal Medicine, The Royal London Hospital, London, UKIntroduction: Whether clinically implementable exercise interventions in people receiving hemodialysis
(HD) therapy improve health-related quality of life (HRQoL) remains unknown. The PrEscription of intra-
Dialytic exercise to improve quAlity of Life (PEDAL) study evaluated the clinical benefit and cost-
effectiveness of a 6-month intradialytic exercise program.
Methods: In a multicenter, single-blinded, randomized, controlled trial, people receiving HD were randomly
assigned to (i) intradialytic exercise training (exercise intervention group [EX]) and (ii) usual care (control group
[CON]). Primary outcome was change in Kidney Disease Quality of Life Short-Form Physical Component
Summary (KDQOL-SF 1.3 PCS) from baseline to 6 months. Cost-effectiveness was determined using health
economic analysis; physiological impairment was evaluated by peak oxygen uptake; and harms were recorded.
Results: We randomized 379 participants; 335 and 243 patients (EX n¼ 127; CON n¼ 116) completed baseline
and 6-month assessments, respectively. Mean difference in change PCS from baseline to 6 months between
EX and CON was 2.4 (95% confidence interval [CI]: 0.1 to 4.8) arbitrary units (P ¼ 0.055); no improvements
were observed in peak oxygen uptake or secondary outcome measures. Participants in the intervention group
had poor compliance (47%) and poor adherence (18%) to the exercise prescription. Cost of delivering inter-
vention ranged from US$598 to US$1092 per participant per year. The number of participants with harms was
similar between EX (n ¼ 69) and CON (n ¼ 56). A primary limitation was the lack of an attention CON. Many
patients also withdrew from the study or were too unwell to complete all physiological outcome assessments.
Conclusions: A 6-month intradialytic aerobic exercise program was not clinically beneficial in improving
HRQoL as delivered to this cohort of deconditioned patients on HD.
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International Reports (2021) 6, 2159–2170patients receiving HD therapy globally, but disability
and associated symptoms remain highly prevalent ac-
counting for more life years lost to disability.1 In the
UK, 48% of the HD population report severe functional
dependencies,2 which impact on HRQoL.3 Components
of HRQoL, particularly the domain of physical func-
tioning, stand out as the strongest predictor of sur-
vival, hospitalizations, and morbidity.4 Knight et al.5
and Lowrie et al.6 report multiple symptoms that2159
CLINICAL RESEARCH SA Greenwood et al.: The PEDAL Trialaffect the physical component of HRQoL.7 Moreover,
higher levels of physical activity are associated with
better scores in HRQoL measures, physical functioning,
depression, and burden of kidney disease symptoms.8
The physical component of HRQoL, therefore, may
be targeted with interventions to enhance physical
activity. In patients receiving HD therapy, systematic
reviews indicate that a range of exercise training in-
terventions improve physical function and alleviate
disability symptoms.9–22 Of particular interest are
studies investigating intradialytic exercise, as the
environment of unit-based HD provides a platform for
longer-term sustainable implementation of exercise
rehabilitation programs.23 The pre-existing need for
patients to attend for standard thrice weekly, 4 hour-
long HD sessions provides an opportunity to deliver
a structured and supervised rehabilitation program
with reduced patient burden regarding time, effort,
and travel costs.24,25 Thus, physical activity behaviors
could be promoted using an implementation model that
integrates physical activity into the main health care
system for patients receiving HD therapy.
Nevertheless, very few dialysis units have chosen to
implement this physical rehabilitation option in the
UK. A barrier to implementation has been a lack of
high-quality, adequately powered randomized
controlled trials of intradialytic exercise with patient-
reported outcomes (HRQoL), health economics (cost-
effectiveness), and harms (serious adverse events
[SAEs]) as the primary outcomes. Thus, the balance of
benefits to costs and harms has been impossible to
evaluate. Consequently, the PrEscription of intra-
Dialytic exercise to improve quAlity of Life (PEDAL)
trial was commissioned by the National Institute for
Health Research to evaluate whether intradialytic ex-
ercise was able to improve HRQoL in patients receiving
HD therapy. The primary objective was to determine,
in stage 5 chronic kidney disease (CKD) patients
receiving maintenance HD, whether usual care
augmented by intradialytic exercise training for a
period of 6 months improved KDQOL-SF 1.3 PCS.METHODS
Trial Design and Oversight
We conducted this pragmatic prospective randomized
controlled trial in 5 regions (London, Scotland, Wales,
North-West England, and Midlands), across a total of
12 HD units, in the UK. The trial recruited prevalent
patients with stage 5 dimensions of CKD receiving HD
therapy. Briefly, the intervention consisted of using a
modified cycle ergometer to perform aerobic exercise in
a semirecumbent position, 3 times per week during the
first 2 hours of HD. Twice per week, after the aerobic2160cycling exercise, participants completed lower ex-
tremity muscular conditioning exercises. These
included 3 sets of 10 to 15 repetitions of dynamic
resistance exercises for all major muscle groups. All
exercises were performed against body weight before
progression with ankle weights and TheraBands
(Akron, OH). The exercise program was delivered and
supervised by physiotherapy assistants.
London Fulham Research Ethics Committee
approved the protocol (14/LO/1851), and all the par-
ticipants provided written informed consent. The
study was registered prospectively (ISRCTN
N83508514). The trial protocol and details on inclusion/
exclusion criteria, randomization procedure, and ex-
ercise intervention and prescription have been
described elsewhere.26 The Consolidated Standards of
Reporting Trials Extension for Patient Report Out-
comes also suggested reporting all the multi-item scales
from the KDQOL-SF instrument.
Primary Outcome
The primary outcome for this study was the change in
KDQOL-SF 1.3 PCS from baseline to 6 months.27 The
KDQOL-SF 1.3 instrument was chosen because of its
validity in patients with CKD and inclusion of a generic
core that has been widely used in CKD and other
populations. The KDQOL-SF 1.3 is a disease-specific
QoL measure that includes 43 kidney disease–targeted
items and 36 items providing a generic core and an
overall health-rating item. The questionnaire was
completed by patients using pen and paper, with
queries answered by research officers blinded to
treatment allocation. Scoring followed currently rec-
ommended methods.28 Thus, the PCS score can be
interpreted as follows: a score above or below 50 is
above or below the average, respectively, in the US
general population, whereas a 1-point difference in the
score is one-tenth of a SD. Analysis of within-trial
change in the KDQOL-SF 1.3 PCS score from baseline,
adjusted for baseline levels and randomization mini-
mization variables, suggested that the study had 80%
power to detect a 4-point difference with only 87
participants per group (with complete data at baseline
and 6-month follow-up).
Secondary Outcomes
HRQoL, Cost-Effectiveness, and Harms
From the KDQOL-SF 1.3, the multi-item scale of energy/
fatigue and the kidney disease–targeted items (burden
of kidney disease) were presented as prespecified. In
addition, the remaining 7 multi-item scales were pre-
sented. Then, a generic preference-based measure of
HRQoL was obtained using the EuroQol 5-dimension
descriptive system (EQ-5D-5L).29 The EQ-5D-5LKidney International Reports (2021) 6, 2159–2170
SA Greenwood et al.: The PEDAL Trial CLINICAL RESEARCHcomprises the following 5 dimensions: mobility, self-
care, usual activities, pain/discomfort, and anxiety/
depression. The EQ—visual analog scale was also ob-
tained, whereby participants reported their self-rated
evaluation of their health state on a 0 to 100 visual
analog scale. Costs of delivering the PEDAL interven-
tion were calculated, including exercise equipment,
assumed to cost £1000 with a lifetime of 10 years and
maintenance costs of £50 per year. Staff costs were
assumed to include one 0.6 full-time equivalent
physiotherapy assistant (mid band 4 Agenda for
Change scale, annual employer costs from £25,866
outside London to £34,787 in London) per 12 to 20
participants (to reflect different geographic spacing of
kidney units in rural and urban areas) and one 1.0
full-time equivalent supervisor (mid band 8 Agenda for
Change, annual employer costs from £55,078.00 outside
London to £71,418.96 in London) per 80 participants.
Physical Function
Upper limits of exercise tolerance were assessed by
peak oxygen uptake determined by an incremental
cycling protocol.26 Physical function limitations were
assessed by the sit-to-stand-6030 and gait speed in 10
m.31 Physical activity behaviors were captured by the
International Physical Activity Questionnaire Short-
Form32; ability to undertake activities of daily livings
was recorded by the Duke Activity Status Index33; and
fear of falling was assessed by the Tinetti Falls Efficacy
Scale.34
Cardiovascular Risk and Clinical Measures
Arterial stiffness was assessed by the carotid–femoral
pulse wave velocity,35 measured using the Vicorder
system (Skidmore Industries, UK) and by following the
current recommendations.35 Measures of body mass
index and waist circumference were also recorded.
Clinical data included cause of kidney disease, comor-
bidities, routine clinical blood tests (hemoglobin, serum
phosphate, and parathyroid hormone), and medications
(including erythropoiesis-stimulating agents).
Harms
Harms were actively recorded in both groups by the
physiotherapy assistants from baseline to the end of the
6-month follow-up period (n ¼ 335). Relationship to
the intervention was evaluated by the lead clinician at
each center, who was not blinded to treatment alloca-
tion. SAEs were reviewed by a data safety monitoring
committee; rules for stopping the trial were that the
committee identified a marked increase in expected or
unexpected SAEs owing to the testing or intervention
procedures. Data on hospitalizations and deaths (all-
cause mortality and cardiovascular mortality) were
collected by reviews of clinical databases and records at
each study visit.Kidney International Reports (2021) 6, 2159–2170Compliance and Adherence (Fidelity) to Exercise
Prescription
General compliance was recorded as the percentage of
exercise sessions completed out of the total prescribed
for the 6-month follow-up period. Adherence (fidelity)
was recorded as the percentage of patients who
adhered exactly to the prescribed exercise (cycling and
muscle conditioning exercises) at the prescribed in-
tensity and cycling time duration for each session
across the 6 months. In addition, the percentage of
patients who temporarily (>2 weeks) paused exercise
was noted. These data were recorded by physiotherapy
assistants through completion of sessional exercise
diaries.
Statistical Analyses
The primary outcome measure (change from baseline to
6 months in KDQOL-SF 1.3 PCS) was compared between
the control and intervention groups using a normal
linear model adjusting for baseline KDQOL-SF 1.3 PCS
and the randomization minimization variables (age,
gender, diabetes status). The findings are presented as
the adjusted mean difference (95% CI) between the
treatment groups. Significance was set at P # 0.05. The
main analysis was carried out on research participants
with PCS assessments at baseline and 6 months. A total
of 2 sensitivity analyses were also carried out, first
imputing a score of 0 for those who died before 6
months and second based on all participants with a
baseline PCS using the method of multiple imputation.
As results were consistent between methods, only the
main analysis is reported herein.
Secondary continuous outcomes were analyzed as
for the primary outcome. For health economic data, we
estimated the mean between-group difference in costs
of the intervention and the mean between-group dif-
ference in quality-adjusted life years accrued by par-
ticipants during the study, estimated as the area under
the health utility curve from study entry (i.e., ran-
domized and attended baseline visit) to follow-up (6
months after). Costs in the CON were set to 0. Estimated
between-group differences in cost and quality-adjusted
life years were obtained by the method of recycled
prediction in 5000 bootstrap samples. The distribution
of these quantities was summarized and presented
graphically in the incremental cost effectiveness plane.
Time-to-event outcomes (cardiovascular and all-cause
mortality) were calculated as time from randomization
and were compared between treatment groups using
Cox proportional hazard regression models. The results
are reported as the adjusted hazard ratio for interven-
tion versus control (95% CI). Data involving counts of
events (hospitalizations) were compared between
treatment groups using negative binomial regression2161
CLINICAL RESEARCH SA Greenwood et al.: The PEDAL Trialmodels adjusting for length of follow-up. The results
are reported as adjusted rate ratio (95% CI). Harms
(SAEs) were tabulated by system organ class and body
system using the Medical Dictionary for Regulatory
Activities Terminology.36 Recurrent events were
counted separately. Compliance and adherence data
were tabulated and presented visually.RESULTS
Patient flow, including recruitment to and retention in
the trial, is detailed in Figure 1. A total of 2409 patients
were screened for eligibility. Nevertheless, 410 were
not eligible per inclusion criteria, 660 patients declined
to participate, and 990 patients were not eligible to
participate owing to competing trials in this same
population within the UK. A total of 335 participants
attended a baseline study visit, 175 patients who were
randomized to EX and 160 participants to CON. The
primary outcome was known for 243 participants
(73%) who attended a baseline visit, 116 participants
(66%) in the exercise group, and 127 participants
(79%) in the usual care group. More patients withdrew
from EX (40; 34.5%) than CON (15; 11.8%) owing to
participant decision, physician recommendation
because of medical concerns, and transplantation.
Apart from an increased number of smokers in the
group of patients who withdrew from EX, no obvious
differences in characteristics of the withdrawn and not
withdrawn groups were present (Table 1).
Effect of Intradialytic Exercise Training on
HRQoL
For the primary outcome, the mean difference in the
change in PCS from baseline to 6 months between EX
and CON was 2.4 (95% CI: 0.1 to 4.8) arbitrary unit
and was not statistically significant (P ¼ 0.055). Simi-
larly, other measures of HRQoL (energy/fatigue,
burden of kidney disease, EQ-5D-5L, and EQ-5D visual
analog scale: Table 2; the remaining 7 multi-item scales
from the KDQOL-SF: Supplementary Table S1) were all
unchanged by the intervention.
Cost-Effectiveness
The mean (SD) of the area under the EQ-5D-5L curve
was 0.665 (0.248) in the CON and 0.653 (0.269) in the
intervention group. The mean difference between
treatment and intervention groups obtained using the
method of recycled predictions was 0.012 (95%
CI: 0.069 to 0.043), suggesting no difference in QoL
between the intervention and CONs (Figure 2 for an
example analysis calculated using a low staff-to-patient
ratio, outside London). No significant subgroup effects
were found for age, sex, or diabetes at baseline.2162Costs from different sources under different sce-
narios for staff costs are found in Table 3. Average total
costs per patient in 6 months range from £232 (US$299)
(95% CI: £204–£259) to £424 (US$546) (95% CI: £374–
£474), depending on location and staff to patient ratio.
The main cost factor was the staff cost for delivering
the exercise sessions.
Effect of Intradialytic Exercise Training on Sec-
ondary Outcomes
Consistent with the lack of change in HRQoL, there
were no statistically significant or absolute changes in
physical function outcomes (Table 4), cardiovascular
risk (arterial stiffness: Table 4), or clinical measures
(routine clinical blood tests and medications: data not
found). Although mortality was not influenced by the
intervention, the number of hospitalizations tended to
be higher in the EX group (Table 5). This trend was
driven by 11 patients in the EX group who were each
hospitalized more than 4 times during the trial for
reasons deemed unlikely to be related to the inter-
vention (e.g., fistula issues); in contrast, only 2 pa-
tients in the CON group were hospitalized more than 4
times.
Harms
There was no noticeable increase in SAEs in the exer-
cise group (Table 6). Nevertheless, there was 1 notice-
able SAE: an individual with type 1 diabetes and
autonomic neuropathy experienced severe episodes of
symptomatic hypotension that were possibly exacer-
bated by the intervention. The participant was
withdrawn.
Compliance and Adherence (Fidelity) to the
Exercise Prescription
A median (interquartile range) of 47 (28–77)% of ex-
ercise training sessions prescribed was completed by
participants in EX. Nevertheless, only 18% of patients
adhered exactly to the prescribed exercise type, in-
tensity, and duration. Moreover, during the 6-month
observation period, only 42% of participants avoided
temporary cessation of the exercise intervention
(Table 7). Reasons reported were fatigue and intercur-
rent medical events (Figure 3).
DISCUSSION
The aim of the PEDAL trial was to evaluate the clinical
value of a 6-month intradialytic exercise program on
QoL, compared with usual care, for patients receiving
HD therapy. The PEDAL trial was novel in that it was
the first to evaluate intradialytic exercise as would most
likely be implemented, should health service commis-
sioners include exercise training as part of the serviceKidney International Reports (2021) 6, 2159–2170
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o Participant decision (n=23)
o Physician recommendation (n=7)
o Adverse event (n=2)
o Moved away (n=1)
Analysed (n=116)
Did not attend 6-month visit (n=59)
• Died (n = 3)
• Withdrawn (n=40)
o Adverse event attributed to the intervention (n=1)
o Adverse event not attributed to the intervention (n=5)
o Participant decision (n=8)
o Physician recommendation (n=9)
o Moved away (n=1)
o Transplanted (n=13)
o Other (n=2: initiated PD; recruited to another study)
o Unknown (n=1)
• Did not attend (n=16)
o Missed visit (n=4)
o Subsequently withdrawn due to participant decision 
(n=5)
o Subsequently died (n=4)
o Lost to follow up (n=3)
Did not attend 6-month visit (n=33)
• Died (n = 4)
• Withdrawn (n=15)
o Adverse event attributed to the intervention (n=0)
o Adverse event not attributed to the intervention (n=1)
o Participant decision (n=4)
o Physician recommendation (n=1)




• Did not attend (n=14)
o Missed visit (n=7)
o Subsequently withdrawn due to participant decision 
(n=7)
o Subsequently died (n=0)
o Lost to follow up (n=0)
Analysed (n=127)Analysis
Participants randomly assigned who attended baseline visit (n=335)
Enrollment Randomly assigned (n= 379)
Assessed for eligibility (N = 
2429)
Excluded (n=2050)
• Did not meet inclusion criteria (n= 410)
• Declined to participate (n= 650)
• Other reasons eg: competing trials
(n=990)
Withdrawal
Figure 1. CONSORT diagram of the flow of patients across the various phases of the trial. CONSORT, Consolidated Standards of Reporting
Trials; PD, progression disease.
SA Greenwood et al.: The PEDAL Trial CLINICAL RESEARCHspecification for in-center HD. Unfortunately, as
delivered, the PEDAL program did not statistically
improve HRQoL, as assessed by the KDQOL-SF 1.3Kidney International Reports (2021) 6, 2159–2170PCS (P ¼ 0.055), nor did it statistically improve QoL
as assessed by the prespecified secondary outcomes
of EQ-5D-5L, EQ-5D visual analog scale, or the2163
Table 1. Baseline characteristics of all patients in the trial, stratified by group, and according to withdrawal from the trial
Baseline characteristic
CON, not withdrawn EX, not withdrawn CON, withdrawn EX, withdrawn
N Summary N Summary N Summary N Summary
Age
Mean (SD) 145 59.8 (14.1) 135 60.5 (15.0) 15 52.8 (19.9) 40 56.8 (13.3)
Median (Q1, Q3) 59.7 (50.5, 71.0) 62.1 (47.9, 72.9) 56.1 (34.7, 61.2) 56.3 (49.6, 64.3)
Gender
n (%) Female 145 55 (38) 135 56 (42) 15 4 (27) 40 11 (28)
Ethnicity
n (%) White 145 67 (46) 135 73 (54) 15 10 (67) 40 19 (48)
n (%) Black Caribbean 26 (18) 17 (13) 1 (7) 3 (8)
n (%) Black African 33 (23) 24 (18) 1 (7) 10 (25)
n (%) South Asian 15 (10) 16 (129) 2 (13) 6 (15)
n (%) Chinese 1 (1) 1 (1) 0 (0) 0 (0)
n (%) Othera 3 (2) 4 (3) 1 (7) 2 (5)
Weight (kg)
Mean (SD) 143 80.8 (20.5) 135 79.2 (18.8) 15 82.5 (13.8) 40 82.8 (24.8)
Median (Q1, Q3) 77.0 (66.1, 92.2) 76.4 (65.4, 90.8) 83.0 (67.5, 91.5) 78.5 (67.4, 90.7)
BMI (kg/m2)
Mean (SD) 143 28.8 (6.5) 135 28.5 (6.5) 15 28.8 (5.5) 40 29.2 (8.8)
Median (Q1, Q3) 28.0 (24.5, 32.0) 27.0 (23.8, 32.2) 27.8 (24.2, 32.4) 27.6 (22.3, 32.6)
Smoking
n (%) Current 145 19 (13.1) 135 18 (13.3) 15 0 (0.0) 40 5 (12.5)
n (%) Former 45 (31.0) 39 (28.9) 4 (26.7) 10 (25.0)
n (%) Never 81 (55.9) 78 (57.8) 11 (73.3) 25 (62.5)
SBP (mm Hg)
Mean (SD) 142 138.6 (23.4) 135 134.4 (21.3) 15 133.9 (22.6) 40 134.1 (17.5)
Median (Q1, Q3) 138.0 (121.8, 153.9) 133.7 (121.3, 147.5) 130.0 (115.0, 152.2) 131.5 (121.0, 142.8)
DBP (mm Hg)
Mean (SD) 142 73.4 (13.7) 135 72.6 (15.4) 15 75.5 (15.4) 40 76.9 (10.0)
Median (Q1, Q3) 73.3 (63.2, 81.7) 71.3 (61.3, 82.7) 74.0 (67.0, 80.7) 76.8 (70.8, 81.5)
Peripheral vascular disease
n (%) Yes 145 6 (4.1) 135 5 (3.7) 15 0 (0.0) 40 0 (0.0)
Diabetes
n (%) Yes 145 59 (40.7) 135 52 (38.5) 15 6 (40.0) 40 15 (37.5)
Hypertension
n (%) Yes 145 116 (80.0) 135 101 (74.8) 15 11 (73.3) 40 33 (82.5)
Hyperlipidemia
n (%) Yes 145 39 (26.9) 135 23 (17.0) 15 4 (26.7) 40 5 (12.5)
Previous MI
n (%) Yes 145 21 (14.5) 135 14 (10.4) 15 0 (0.0) 40 6 (15.0)
Heart failure
n (%) Yes 145 17 (11.7) 135 14 (10.4) 15 0 (0.0) 40 1 (2.5)
Cerebrovascular events
n (%) Yes 145 17 (11.7) 135 8 (5.9) 15 1 (6.7) 40 0 (0.0)
Cardiovascular
n (%) Yes 145 25 (17.2) 135 30 (22.2) 15 2 (13.3) 40 12 (30.0)
Musculoskeletal and orthopedic condition
n (%) Yes 145 19 (13.1) 135 16 (11.9) 15 1 (6.7) 40 7 (17.5)
Hb
Mean (SD) 141 110.2 (12.1) 127 109.8 (14.1) 15 118.1 (14.2) 37 108.9 (15.8)
Median (Q1, Q3) 109.0 (103.0, 119.0) 110.0 (102.0, 118.5) 115.0 (109.0, 124.0) 110.0 (100.0, 120.0)
CRP (mg/l)
Mean (SD) 139 15.3 (21.1) 125 11.9 (15.9) 15 12.5 (16.4) 36 21.1 (26.6)
Median (Q1, Q3) 6.6 (3.1, 18.1) 6.0 (3.0, 14.1) 8.0 (4.5, 11.0) 10.9 (4.3, 28.1)
Dialysis efficiency (%)
Mean (SD) 141 71.2 (8.4) 125 71.9 (7.3) 15 71.0 (11.3) 37 71.6 (7.9)
Median (Q1, Q3) 72.0 (66.0, 77.0) 73.0 (69.0, 76.5) 74.0 (68.0, 77.8) 71.8 (66.0, 77.0)
BMI, body mass index; CON, control group; CRP, C-reactive protein; DBP, diastolic blood pressure; EX, exercise intervention group; Hb, hemoglobin; MI, myocardial infraction; Q, quartile;
SBP, systolic blood pressure.
Continuous variables are revealed as mean (SD) and median (Q1, Q3).
aIndian, Pakistani, and Bangladeshi.
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Table 2. Response of quality of life to the PEDAL intervention, as assessed by KDQOL-SF 1.3 and EQ-5D-5L questionnaires
Outcome measure na Baseline Month 6
Adjusted mean difference in
change between EX and CON groupsb P valuec
Primary outcome
KDQOL-SF 1.3 PCS (AU)
CON 120 32.9 (11.3) 31.8 (11.3) 2.4 (0.1 to 4.8) 0.06
EX 114 33.8 (10.6) 34.8 (11.6)
Secondary outcomes
KDQOL-SF 1.3 Energy/fatigue (AU)
CON 122 39.8 (26.0) 41.4 (24.9) 0.1 (5.6 to 5.8) 0.97
EX 114 40.3 (27.2) 41.4 (26.4)
KDQOL-SF 1.3 burden of kidney disease (AU)
CON 122 36.0 (28.6) 37.3 (29.7) 1.4 (7.0 to 4.1) 0.61
EX 113 37.3 (27.7) 36.9 (29.0)
EQ-5D-5L health utility score (AU)
CON 121 0.69 (0.25) 0.68 (0.26) 0.01 (0.04 to 0.07) 0.69
EX 111 0.71 (0.22) 0.70 (0.25)
EQ-5D visual analog scale (0–100 scale)
CON 121 59.4 (22.7) 59.3 (20.9) 3.5 (1.0 to 8.1) 0.13
EX 111 60.7 (22.2) 63.7 (19.3)
AU, arbitrary unit; CON, control group; EQ-5D, EuroQol 5-dimension descriptive system; EX, exercise intervention group; KDQOL-SF 1.3, Kidney Disease Quality of Life Short-Form; PCS,
physical component summary; PEDAL, PrEscription of intraDialytic exercise to improve quAlity of Life.
aNumber of participants with baseline and 6-month data available.
bAdjusting for baseline data and the randomization minimization variables (age, gender, diabetes status).
cComparison between the control and intervention groups using a normal linear model.
Data are mean (SD) or mean (95% confidence interval). CON—usual care maintenance hemodialysis. EX—intradialytic exercise training plus usual care maintenance hemodialysis.
SA Greenwood et al.: The PEDAL Trial CLINICAL RESEARCHKDQOL-SF 1.3 multi-item scales of energy/fatigue
and burden of kidney disease (Table 2).
The lack of statistical improvement in the PCS can be
explained in part by the PEDAL participants having
poor compliance (only 47% of prescribed exercise
sessions were completed) and very poor adherence
(only 18% of patients adhered to the prescribed pro-
gression of overload regarding type, intensity, and
duration of exercise) to the exercise intervention. ByFigure 2. Cost-effectiveness: estimated differences in cost and QALYs
on the ICER plane for a low staff-to-patient ratio, outside London (5000
bootstrap samples). ICER, incremental cost effectiveness ratio; QALY,
quality-adjusted life year.
Kidney International Reports (2021) 6, 2159–2170design, the PEDAL trial aimed to have inclusive in-
clusion criteria. Consequently, baseline peak aerobic
capacity values of 12 ml/min/kg were considerably
lower than typically reported in previous studies
(approximately 18 ml/min/kg).10,12,18 This observation,
combined with extremely low scores in physical per-
formance (sit-to-stand and gait speed tests), confirms
that the PEDAL cohort consisted of participants with
severely low functional capacity. Arguably, this makes
the PEDAL cohort more representative and its findings
generalizable to the current HD population. Neverthe-
less, perhaps including such participants prevented
benefits of the exercise intervention being realized in
the relatively short 6-month intervention, and it is
possible that some of these highly compromised par-
ticipants may require a slower rate of overload pro-
gression and adaptation/adjustment periods to an
aerobic intradialytic exercise intervention. Poor
compliance and adherence to implemented renal exer-
cise programs in clinical practice is well documented,
with more than 50% of the patients starting exercise
reportedly dropping out by 6 months, often owing to
fatigue and being unwell.18,37,38
That the PEDAL program was not effective to in-
crease PCS warrants comparison with previous studies.
A Cochrane review completed in 2011 concluded that
exercise was beneficial for HRQoL in patients with
CKD, but unfortunately no meta-analysis or risk of bias
assessment was performed, and many of the included
studies were not representative of the HD population.9
Other reviews have concluded positive effects of2165
Table 3. Costs per patient to deliver the PEDAL intervention in the 6-month follow-up period
Cost source
Outside London London
Low staff-to-patient ratio High staff-to-patient ratio Low staff-to-patient ratio High staff-to-patient ratio
Equipment purchasing and maintenance (£) 9 (8–10) 9 (8–10) 9 (8–10) 9 (8–10)
Staff delivering exercise sessions (£) 204 (180–228) 341 (300–381) 237 (209–265) 395 (348–441)
Training and oversight (£) 18 (16–20) 18 (16–20) 20 (18–23) 20 (18–23)
Total cost per patient in 6 months (£) 232 (204–259) 368 (324–412) 266 (235–298) 424 (374–474)
Estimated difference in cost (recycled predictions) (£) 234 (209–260) 372 (331–414) 269 (240–299) 428 (380–476)
PEDAL, PrEscription of intraDialytic exercise to improve quAlity of Life.
Data are mean (95% confidence interval). Estimated differences in cost obtained by the method of recycled prediction in 5000 bootstrap samples, setting cost in the control group to 0,
adjusted for age, sex, and diabetes at baseline.
CLINICAL RESEARCH SA Greenwood et al.: The PEDAL Trialexercise but not on PCS16,21,38 or have relied on studies
at high risk of bias and with considerable heterogene-
ity.17,20 Previous meta-analyses have also included
extradialytic exercise programs19,39,40 and intradialytic
exercise programs that were intensively supervised (e.g.,
Ouzouni et al.41) or studies that have delivered pro-
gressive resistance training as opposed to aerobic
cycling alone.10,15,42 In this regard, 1 meta-analysis22
usefully compared aerobic versus progressive resis-
tance training versus combined exercise; only progres-
sive resistance training increased PCS. Detailed analysis
of the very few empirical studies included in reviewsTable 4. Response of secondary outcome measures to the PEDAL interve
Outcome measure na Baseline
Peak aerobic capacity (VO2 peak, l/min)
CON 68 0.97 (0.38)
EX 75 0.95 (0.42)
Peak aerobic capacity (VO2 peak, ml/min/kg)
CON 68 11.9 (4.5)
EX 74 11.8 (5.3)
Arterial stiffness by pulse wave velocity (ms)22
CON 78 8.10 (6.78, 9.29)
EX 78 7.92 (6.62, 9.09)
DASI (AU)
CON 121 23.1 (13.1)
EX 112 24.9 (13.3)
IPAQ total physical activity (MET, min/wk) [ln(x þ 10)]
CON 118 423.8 (39.0, 1465.4)
EX 106 709.5 (153.8, 2515.1)
Gait speed in 10 m (m/s)
CON 84 0.86 (0.30)
EX 79 0.94 (0.29)
Sit-to-stand 60 s (no. of repetitions)
CON 87 13.8 (6.6)
EX 82 15.8 (7.1)
Tinetti Falls Efficacy Scale (AU) [ln(x)]
CON 122 22.5 (10.2, 46.8)
EX 112 23.0 (11.8, 49.2)
AU, arbitrary units; CON, control group; DASI, Duke Activity Status Index; EX, exercise interventi
task; PEDAL, PrEscription of intraDialytic exercise to improve quAlity of Life; VO2, maximum ra
aNumber of participants with baseline and 6-month data available.
bAdjusting for baseline data and the randomization minimization variables (age, gender, diabe
cComparison between the control and intervention groups using a normal linear model.
Data are mean (SD), median (IQR), or mean (95% confidence interval); some variables were tran
maintenance hemodialysis; EX—intradialytic exercise training plus usual care maintenance he
2166that do reveal positive effects of aerobic intradialytic
exercise on QoL reveals that they have often used
interventions that would be difficult to implement in
routine care.41 A recent study by Jeong et al.43 found
no significant improvements in physical function or
QoL with a combined oral protein supplement and
intradialytic cycling program. The authors suggested
that a more comprehensive lifestyle management
approach would be required to elicit improvements
in these parameters. Taken together with the
results reported herein, it is highly unlikely that
clinically implementable intradialytic aerobic exercisention
Month 6
Adjusted mean difference in change
between EX and CON groupsb P valuec
0.96 (0.37) 0.05 (0.03 to 0.12) 0.22
0.98 (0.43)
11.8 (4.2) 0.75 (0.20 to 1.71) 0.12
12.4 (5.7)
7.78 (6.97, 9.13) 1.01 (0.97–1.06) 0.54
7.88 (6.98, 9.27)
22.7 (13.4) 0.35 (2.23 to 2.93) 0.79
24.1 (14.3)
353.2 (46.1, 1033.1) 1.36 (0.84–2.21) 0.21
591.0 (111.8, 1793.2)
0.87 (0.29) 0.01 (0.04 to 0.06) 0.73
0.94 (0.30)
14.4 (7.0) 1.02 (0.42 to 2.47) 0.16
17.1 (8.1)
24.5 (11.0, 50.0) 0.94 (0.80–1.12) 0.49
24.5 (11.0, 46.2)
on group; IPAQ, International Physical Activity Questionnaire; MET, metabolic equivalent
te of oxygen consumption.
tes status): note variables analyzed as log-transformed values are given as ratios.
sformed to enhance model fit: transformations are given in [brackets]. CON—usual care
modialysis.
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CON 160 84 (0.54) 1.39 (0.93–2.08) 0.109
EX 175 132 (0.85)
No. of events






CON 160 9 (5.8) 1.19 (0.48–2.94) 0.71
EX 174 10 (6.5)
Cardiovascular
mortality
CON 160 3 (1.9) N/A N/A
EX 174 2 (1.3)
CON, control group; EX, exercise intervention group; N/A, not applicable; PEDAL, PrEscription
of intraDialytic exercise to improve quAlity of Life.
aNumber of participants with baseline and 6-month data available.
bIncident rate ratios have been calculated in negative binomial regression predicting
number of hospitalizations from treatment, adjusting for age, sex, and diabetes at
baseline.
cFor all-cause mortality, survival was adjusted for age, sex, and diabetes at baseline; for
cardiovascular mortality, survival was adjusted for age and diabetes at baseline.
dHazard ratios have been calculated in Cox proportional hazard regression models
predicting survival from treatment.
CON—usual care maintenance hemodialysis. EX—intradialytic exercise training plus
usual care maintenance hemodialysis. N/A—as numbers too small to analyze.
Table 6. Number of patients with at least 1 SAE by MedDRA system
organ class during the PEDAL trial
Variable All, n (%) CON, n (%) EX, n (%)
Number of randomized
patients who attended baseline
visit
335 160 175
Number of patients with any event 125 56 (35.0) 69 (39.4)
Blood and lymphatic system
disorders
2 (0.6) 0 (0.0) 2 (1.1)
Cardiac disorders 15 (4.5) 6 (3.8) 9 (5.1)
Congenital, familial, and genetic
disorders
1 (0.3) 1 (0.6) 0 (0.0)
Gastrointestinal disorders 14 (4.2) 4 (2.5) 10 (5.7)
General disorders and
administration site conditions
17 (5.1) 12 (7.5) 5 (2.9)
Hepatobiliary disorders 3 (0.9) 1 (0.6) 2 (1.1)
Infections and infestations 47 (14.0) 18 (11.2) 29 (16.6)
Injury, poisoning, and procedural
complications
28 (8.4) 12 (7.5) 16 (9.1)
Investigations 5 (1.5) 4 (2.5) 1 (0.6)
Metabolism and nutrition disorders 17 (5.1) 4 (2.5) 13 (7.4)
Musculoskeletal and connective
tissue disorders
4 (1.2) 1 (0.6) 3 (1.7)
Neoplasms benign, malignant and
unspecified (including cysts and
polyps)
1 (0.3) 0 (0.0) 1 (0.6)
Nervous system disorders 8 (2.4) 3 (1.9) 5 (2.9)
Psychiatric disorders 4 (1.2) 1 (0.6) 3 (1.7)
Renal and urinary disorders 1 (0.3) 1 (0.6) 0 (0.0)
Reproductive system and breast
disorders
2 (0.6) 1 (0.6) 1 (0.6)
Respiratory, thoracic and
mediastinal disorders
13 (3.9) 3 (1.9) 10 (5.7)
Skin and subcutaneous tissue
disorders
1 (0.3) 0 (0.0) 1 (0.6)
Social circumstances 1 (0.3) 1 (0.6) 0 (0.0)
Surgical and medical procedures 37 (11.0) 13 (8.1) 24 (13.7)
Vascular disorders 10 (3.0) 6 (3.8) 4 (2.3)
CON, control group; EX, exercise intervention group; MedDRA, Medical Dictionary for
Regulatory Activities; PEDAL, PrEscription of intraDialytic exercise to improve quAlity of
Life; SAE, serious adverse event.
CON—usual care maintenance hemodialysis. EX—intradialytic exercise training plus
usual care maintenance hemodialysis.
able 7. Summary of exercise compliance and adherence to the
EDAL trial intervention during the 6-month follow-up period
ompliance (percentage of expected sessions completed)
ample size (n) 175
edian (IQR) 47 (28–77)
mporary (>2 wk) cessation of exercise
ample size (n) 119
(%) 69 (58)
dhered (fidelity to type/intensity/duration) to the exercise prescription
ample size (n) 119
(%) 21 (18)
R, interquartile range; PEDAL, PrEscription of intraDialytic exercise to improve quAlity
f Life.
SA Greenwood et al.: The PEDAL Trial CLINICAL RESEARCHtraining alone can improve QoL at a whole population
level.
In addition to evaluating potential benefits, the
PEDAL study uniquely assessed the cost of delivery of
its intervention by recording harms and using health
economic methods. The number of hospitalizations, all-
cause mortality, and cardiovascular mortality was not
noticeably different between the groups. Although
these results should be interpreted cautiously owing to
the low number of events, there was no increase in SAE
in the exercise group either. The economic cost of
delivering the PEDAL intervention ranged from £464
(US$598) to £848 (US$1092) per participant per year
(depending on pay band of the physiotherapy assis-
tant, whether London weighting was applied, and
staff-to-patient ratio). Note this calculation assumed
that physiotherapy assistants supervised between 6
and 10 participants per dialysis session without
incurring any travel costs and that exercise would be
offered as part of a general physiotherapy service (with
enough capacity to provide absence cover at no addi-
tional cost). It also assumes that patients will only ex-
ercise for between 1 and 2 sessions per week (the
calculation is based on compliance to the PEDAL
intervention, which was only 47%). For comparison
purposes, the cost of delivering cardiac rehabilitation is
£477 (US$614) per person per year,44 equating to costs
of £550 (US$709) to £12,558 (US$16,178) per quality-
adjusted life year gained.45 In contrast, PEDAL had noKidney International Reports (2021) 6, 2159–2170apparent QoL gain, albeit in a relatively short period of
observation of 6 months (cost-effectiveness of rehabilita-
tion programs increases with time44,45). The cost of de-
livery of HD in the UK is approximately £35,000














Figure 3. Number (%) of recorded incidents of temporary cessation (>2 weeks) or missed exercise sessions with reasons.
CLINICAL RESEARCH SA Greenwood et al.: The PEDAL Trialnot clinically effective at a whole sample level, whether
the cost of delivery of intradialytic exercise is justified to
enhance patient choice remains a matter for debate.
Limitations
PEDAL was designed to assess a pragmatic, clinically
implementable intradialytic exercise intervention. By
design, the study relied on a patient-reported outcome
measure for its primary outcome; it is recognized that
the primary limitation of this study was the lack of an
attention CON. In this regard, it is possible that an
experimenter effect explains the 2.4 arbitrary unit in-
crease (albeit nonsignificant) in PCS.47 This interpretation
is supported by the lack of absolute or statistical changes
in objective measures of physical function, cardiovascular
risk, and clinical measures (Table 2), consistent with a
conclusion that intradialytic aerobic exercise per se had
no clinical benefit. In addition, the study was not pow-
ered to detect differences in some secondary outcomes,
including mortality. Nevertheless, we reported these data
to allow a balance of benefits and harms to be evaluated.
Future studies should address these concerns by
including attention control arms and being adequately
powered for all outcome measures. Perhaps the most
important finding of the PEDAL study was the observa-
tion of poor compliance and adherence when intradialytic
exercise was implemented as part of routine care. It is
acknowledged that the lack of absolute or significant
change in objective measures may in part be due to
limitations in the effective implementation of delivering
an adequate dose of exercise stimulus as indicated by the
very low compliance and adherence data. PEDAL was
designed to be a pragmatic intervention, and no addi-
tional strategies to address low compliance or adherence2168were introduced. Thus, future studies need to evaluate
whether there are subgroups of patients who may benefit
from this type of intervention and whether there is scope
to optimize strategies to improve compliance and adher-
ence with intradialytic cycling interventions, imple-
mentation settings, and resources to deliver exercise-
based interventions to improve effectiveness.
CONCLUSIONS
The PEDAL study was a rehabilitation program that
could realistically be commissioned as part of routine
care. Compliance and adherence with the exercise
intervention, as per the study design, were extremely
low. In this inclusive sample of people on HD, many of
whom were severely deconditioned; the findings
therefore suggest that 6 months of intradialytic aerobic
exercise did not improve HRQoL.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
We are grateful to the research assistants, physiotherapy
assistants, and research nurses who facilitated completion
of this study. This study is funded by a grant from the
National Institute for Health Research (grant number:
NIHR-HTA 12/23/09). The views expressed in this publica-
tion are those of the authors and not necessarily those of
the National Health Service, the National Institute for
Health Research, or the Department of Health. The funders
had no role in the design, collection, analysis, and inter-
pretation of the data or writing of this protocol. SM is
supported by NIHR infrasructure in D4D MIC Sheffield, UK.Kidney International Reports (2021) 6, 2159–2170
SA Greenwood et al.: The PEDAL Trial CLINICAL RESEARCHAUTHOR CONTRIBUTIONS
SAG, PK, JHM, ICM, IF, AS, and TM conceived and designed
the study; IF and CMM analyzed the data; SAG, JHM, and
PK interpreted and contextualized the data and drafted the
paper; SAG, JHM, PK, DW, SB, KF, MT, PAK, MK, JB, ICM,
IF, CMM, SK, CR, IDG, CR, MY, PT, SM, TM, and AS revised
the paper; all authors approved the final manuscript.
SUPPLEMENTARY MATERIAL
Supplementary File (PDF)
Table S1. Response of quality of life to the PEDAL
intervention, as assessed by the Kidney Disease Quality




1. GBD Chronic Kidney Disease Collaboration. Global, regional,
and national burden of chronic kidney disease, 1990-2017: a
systematic analysis for the Global Burden of Disease Study
2017. Lancet. 2020;395:709–733. https://doi.org/10.1016/
S0140-6736(20)30045-3.
2. Jassal SV, Karaboyas A, Comment LA, et al. Functional
dependence and mortality in the International Dialysis Out-
comes and Practice Patterns Study (DOPPS). Am J Kidney
Dis. 2016;67:283–292. https://doi.org/10.1053/j.ajkd.2015.09.
024.
3. Stack AG, Molony DA, Rives T, Tyson J, Murthy BV. Associ-
ation of physical activity with mortality in the US dialysis
population. Am J Kidney Dis. 2005;45:690–701. https://doi.
org/10.1053/j.ajkd.2004.12.013.
4. van Loon IN, Bots ML, Boereboom FTJ, et al. Quality of life as
indicator of poor outcome in hemodialysis: relation with
mortality in different age groups. BMC Nephrol. 2017;18:217.
https://doi.org/10.1186/s12882-017-0621-7.
5. Knight EL, Ofsthun N, Teng M, Lazarus JM, Curhan GC. The
association between mental health, physical function, and
hemodialysis mortality. Kidney Int. 2003;63:1843–1851.
https://doi.org/10.1046/j.1523-1755.2003.00931.x.
6. Lowrie EG, Curtin RB, LePain N, Schatell D. Medical outcomes
study short form-36: a consistent and powerful predictor of
morbidity and mortality in dialysis patients. Am J Kidney Dis.
2003;41:1286–1292. https://doi.org/10.1016/s0272-6386(03)
00361-5.
7. Brown SA, Tyrer FC, Clarke AL, et al. Symptom burden in
patients with chronic kidney disease not requiring renal
replacement therapy. Clin Kidney J. 2017;10:788–796. https://
doi.org/10.1093/ckj/sfx057.
8. Li YN, Shapiro B, Kim JC, et al. Association between quality of
life and anxiety, depression, physical activity and physical
performance in maintenance hemodialysis patients. Chronic
Dis Transl Med. 2016;2:110–119. https://doi.org/10.1016/j.
cdtm.2016.09.004.
9. Heiwe S, Jacobson SH. Exercise training for adults with chronic
kidney disease. Cochrane Database Syst Rev. 2011;(10):
CD003236. https://doi.org/10.1002/14651858.CD003236.pub2.Kidney International Reports (2021) 6, 2159–217010. Heiwe S, Jacobson SH. Exercise training in adults with CKD: a
systematic review and meta-analysis. Am J Kidney Dis.
2014;64:383–393. https://doi.org/10.1053/j.ajkd.2014.03.020.
11. Cheema BS, Chan D, Fahey P, Atlantis E. Effect of progressive
resistance training on measures of skeletal muscle hyper-
trophy, muscular strength and health related quality of life in
patients with chronic kidney disease: a systematic review and
meta-analysis. Sports Med. 2014;44:1125–1138. https://doi.
org/10.1007/s40279-014-0176-8.
12. Segura-Ortí E. Ejercicio en pacientes en hemodiálisis: revi-
sión sistemática de la literature [Exercise in hemodialysis
patients: a literature systematic review]. Nefrologia. 2010;30:
236–246. https://doi.org/10.3265/Nefrologia.pre2010.Jan.
10229.
13. Smart N, Steele M. Exercise training in haemodialysis pa-
tients: a systematic review and meta-analysis. Nephrol
(Carlton). 2011;16:626–632. https://doi.org/10.1111/j.1440-
1797.2011.01471.x.
14. Salhab N, Karavetian M, Kooman J, Fiaccadori E, El
Khoury CF. Effects of intradialytic aerobic exercise on he-
modialysis patients: a systematic review and meta-analysis.
J Nephrol. 2019;32:549–566. https://doi.org/10.1007/s40620-
018-00565-z.
15. Sheng K, Zhang P, Chen L, Cheng J, Wu C, Chen J. Intra-
dialytic exercise in hemodialysis patients: a systematic re-
view and meta-analysis. Am J Nephrol. 2014;40:478–490.
https://doi.org/10.1159/000368722.
16. Chung YC, Yeh ML, Liu YM. Effects of intradialytic exercise on
the physical function, depression and quality of life for hae-
modialysis patients: a systematic review and meta-analysis
of randomised controlled trials. J Clin Nurs. 2017;26:1801–
1813. https://doi.org/10.1111/jocn.13514.
17. Pu J, Jiang Z, Wu W, et al. Efficacy and safety of intradialytic
exercise in haemodialysis patients: a systematic review and
meta-analysis. BMJ Open. 2019;9, e020633. https://doi.org/10.
1136/bmjopen-2017-020633.
18. Young HML, March DS, Graham-Brown MPM, et al. Effects of
intradialytic cycling exercise on exercise capacity, quality of
life, physical function and cardiovascular measures in adult
haemodialysis patients: a systematic review and meta-anal-
ysis. Nephrol Dial Transplant. 2018;33:1436–1445. https://doi.
org/10.1093/ndt/gfy045.
19. HuangM, Lv A, Wang J, et al. Exercise training and outcomes in
hemodialysis patients: systematic review andmeta-analysis.Am
J Nephrol. 2019;50:240–254. https://doi.org/10.1159/000502447.
20. Zhao QG, Zhang HR, Wen X, et al. Exercise interventions on
patients with end-stage renal disease: a systematic review.
Clin Rehabil. 2019;33:147–156. https://doi.org/10.1177/
0269215518817083.
21. Clarkson MJ, Bennett PN, Fraser SF, Warmington SA. Exer-
cise interventions for improving objective physical function in
patients with end-stage kidney disease on dialysis: a sys-
tematic review and meta-analysis. Am J Physiol Ren Physiol.
2019;316:F856–F872. https://doi.org/10.1152/ajprenal.00317.
2018.
22. Gomes Neto M, de Lacerda FFR, Lopes AA, Martinez BP,
Saquetto MB. Intradialytic exercise training modalities on
physical functioning and health-related quality of life in pa-
tients undergoing maintenance hemodialysis: systematic2169
CLINICAL RESEARCH SA Greenwood et al.: The PEDAL Trialreview and meta-analysis. Clin Rehabil. 2018;32:1189–1202.
https://doi.org/10.1177/0269215518760380.
23. Global Advocacy for Physical Activity (GAPA) the Advocacy
Council of the International Society for Physical Activity and
Health (ISPAH). NCD prevention: investments [corrected] that
work for physical activity [published correction appears in Br
J Sports Med. 2013;47:246]. Br J Sports Med. 2012;46:709–
712. https://doi.org/10.1136/bjsm.2012.091485.
24. Koufaki P, Greenwood S, Painter P, Mercer T. The BASES
expert statement on exercise therapy for people with chronic
kidney disease. J Sports Sci. 2015;33:1902–1907. https://doi.
org/10.1080/02640414.2015.1017733.
25. Sallis R. Exercise is medicine: a call to action for physicians to
assess and prescribe exercise. Phys Sportsmed. 2015;43:22–
26. https://doi.org/10.1080/00913847.2015.1001938.
26. Greenwood SA, Koufaki P, Macdonald J, et al. The PrEscription
of intradialytic exercise to improve quAlity of Life in patients
with chronic kidney disease trial: study design and baseline
data for a multicentre randomized controlled trial. Clin Kidney J.
2020;14:1345–1355. https://doi.org/10.1093/ckj/sfaa107.
27. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB.
Development of the kidney disease quality of life (KDQOL)
instrument. Qual Life Res. 1994;3:329–338. https://doi.org/10.
1007/BF00451725.
28. Hays K. SF User’s Manual. Santa Monica, CA: RAND; 1997.
29. Herdman M, Gudex C, Lloyd A, et al. Development and pre-
liminary testing of the new five-level version of EQ-5D (EQ-
5D-5L). Qual Life Res. 2011;20:1727–1736. https://doi.org/10.
1007/s11136-011-9903-x.
30. Segura-Orti E, Martinez-Olmos FJ. Test–retest reliability and
minimal detectable change scores for sit-to-stand-to-sit tests,
the six-minute walk test, the one-leg heel-rise test, and hand-
grip strength in people undergoing hemodialysis. Phys Ther.
2011;91:1244–1252. https://doi.org/10.2522/ptj.20100141.
31. Abe Y, Matsunaga A, Matsuzawa R, et al. Determinants of
slow walking speed in ambulatory patients undergoing
maintenance hemodialysis. PLoS One. 2016;11:e0151037.
https://doi.org/10.1371/journal.pone.0151037.
32. Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the
International Physical Activity Questionnaire Short Form
(IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act.
2011;8:115. https://doi.org/10.1186/1479-5868-8-115.
33. Coutinho-Myrrha MA, Dias RC, Fernandes AA, et al. Duke
Activity Status Index for cardiovascular diseases: validation
of the Portuguese translation. Arq Bras cardiol. 2014;102:383–
390. https://doi.org/10.5935/abc.20140031.
34. Tinetti ME, Richman D, Powell L. Falls efficacy as a measure
of fear of falling. J Gerontol. 1990;45:P239–P243. https://doi.
org/10.1093/geronj/45.6.p239.
35. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus
document on arterial stiffness: methodological issues and2170clinical applications. Eur Heart J. 2006;27:2588–2605. https://
doi.org/10.1093/eurheartj/ehl254.
36. MedDRA Maintenance and Support Services Organisation,
Introductory Guide to MedDRA Version 13.1. Chantilly. 2010
37. Greenwood SA, Castle E, Lindup H, et al. Mortality and
morbidity following exercise-based renal rehabilitation in
patients with chronic kidney disease: the effect of programme
completion and change in exercise capacity [published
correction appears in Nephrol Dial Transplant. 2020;35:1452]
Nephrol Dial Transplant. 2019;34:618–625. https://doi.org/10.
1093/ndt/gfy351.
38. Hannan M, Bronas UG. Barriers to exercise for patients with
renal disease: an integrative review. J Nephrol. 2017;30:729–
741. https://doi.org/10.1007/s40620-017-0420-z.
39. Pei G, Tang Y, Tan L, Tan J, Ge L, Qin W. Aerobic exercise in
adults with chronic kidney disease (CKD): a meta-analysis. Int
Urol Nephrol. 2019;51:1787–1795. https://doi.org/10.1007/
s11255-019-02234-x.
40. Barcellos FC, Santos IS, Umpierre D, Bohlke M, Hallal PC.
Effects of exercise in the whole spectrum of chronic kidney
disease: a systematic review. Clin Kidney J. 2015;8:753–765.
https://doi.org/10.1093/ckj/sfv099.
41. Ouzouni S, Kouidi E, Sioulis A, Grekas D, Deligiannis A. Ef-
fects of intradialytic exercise training on health-related qual-
ity of life indices in haemodialysis patients. Clin Rehabil.
2009;23:53–63. https://doi.org/10.1177/0269215508096760.
42. Matsuzawa R, Hoshi K, Yoneki K, et al. Exercise training in
elderly people undergoing hemodialysis: a systematic review
and meta-analysis. Kidney Int Rep. 2017;2:1096–1110. https://
doi.org/10.1016/j.ekir.2017.06.008.
43. Jeong JH, Biruete A, Tomayko EJ, et al. Results from the
randomized controlled IHOPE trial suggest no effects of oral
protein supplementation and exercise training on physical
function in hemodialysis patients. Kidney Int. 2019;96:777–
786. https://doi.org/10.1016/j.kint.2019.03.018.
44. Shields GE, Wells A, Doherty P, Heagerty A, Buck D,
Davies LM. Cost-effectiveness of cardiac rehabilitation: a
systematic review. Heart. 2018;104:1403–1410. https://doi.org/
10.1136/heartjnl-2017-312809.
45. Edwards K, Jones N, Newton J, et al. The cost-effectiveness
of exercise-based cardiac rehabilitation: a systematic review
of the characteristics andmethodological quality of published
literature. Health Econ Rev. 2017;7:37. https://doi.org/10.1186/
s13561-017-0173-3.
46. Baboolal K, McEwan P, Sondhi S, Spiewanowski P,
Wechowski J, Wilson K. The cost of renal dialysis in a UK
setting–a multicentre study.Nephrol Dial Transplant. 2008;23:
1982–1989. https://doi.org/10.1093/ndt/gfm870.
47. Fokkema M, Smits N, Kelderman H, Cuijpers P. Response
shifts in mental health interventions: an illustration of longi-
tudinal measurement invariance. Psychol Assess. 2013;25:
520–531. https://doi.org/10.1037/a0031669.Kidney International Reports (2021) 6, 2159–2170
